{"id":27187,"date":"2024-02-21T10:43:33","date_gmt":"2024-02-21T15:43:33","guid":{"rendered":"https:\/\/myeloma.ca\/?p=27187"},"modified":"2024-02-23T11:49:06","modified_gmt":"2024-02-23T16:49:06","slug":"optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/","title":{"rendered":"Optimisation du traitement d\u2019un my\u00e9lome\u202f: Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Wee-Joo Chng, MBBS, Ph.\u202fD., FRCPath, FRCP, (<em>National University Cancer Institute<\/em><em> <\/em>\u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire.&nbsp;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.myeloma.org\/videos\/optimizing-myeloma-treatment-pomalidomide-based-regimens-compared-asian-myeloma-network-amn?utm_medium=email&amp;utm_source=engagingnetworks&amp;utm_campaign=ash-recap-video&amp;utm_content=ASH+recap+video+Eblast+Final\" target=\"_blank\" rel=\"noopener\" title=\"\">Regardez la vid\u00e9o&#8230;\u00a0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wee-Joo Chng, MBBS, Ph.\u202fD., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire.&nbsp;&nbsp; Regardez la vid\u00e9o&#8230;\u00a0<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,53],"tags":[],"class_list":["post-27187","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=27187"}],"version-history":[{"count":2,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27187\/revisions"}],"predecessor-version":[{"id":27322,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27187\/revisions\/27322"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=27187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=27187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=27187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}